Detail akcie Aurinia Pharma online

Business Summary: Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Aurinia Pharmaceuticals Inc revenues increased 31% to $175.5M. Net loss decreased 28% to $78M. Revenues reflect United States segment increase of 54% to $158M. Lower net loss reflects Interest income increase from $5.1M to $17M (income), Corporate, administration and business d decrease of 12% to $75.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.76 to -$0.54.